See more : Savencia SA (0DTK.L) Income Statement Analysis – Financial Results
Complete financial analysis of Phio Pharmaceuticals Corp. (PHIO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Phio Pharmaceuticals Corp., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Electrotherm (India) Limited (ELECTHERM.BO) Income Statement Analysis – Financial Results
- UFP Technologies, Inc. (UFPT) Income Statement Analysis – Financial Results
- Amplifon S.p.A. (AMFPF) Income Statement Analysis – Financial Results
- Pacific Industries Limited (PACIFICI.BO) Income Statement Analysis – Financial Results
- Fathom Nickel Inc. (FNICF) Income Statement Analysis – Financial Results
Phio Pharmaceuticals Corp. (PHIO)
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in ACT; and PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for use in ACT. It has collaborations with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 21.00K | 138.00K | 15.00K | 19.00K | 34.00K | 71.00K | 399.00K | 97.00K | 0.00 |
| Cost of Revenue | 6.33M | 193.00K | 192.00K | 183.00K | 4.30K | 4.33M | 5.37M | 5.42M | 6.93M | 5.68M | 17.65M | 12.98M | 0.00 |
| Gross Profit | -6.33M | -193.00K | -192.00K | -183.00K | 16.70K | -4.19M | -5.36M | -5.40M | -6.89M | -5.61M | -17.25M | -12.88M | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 79.52% | -3,034.78% | -35,700.00% | -28,400.00% | -20,267.65% | -7,900.00% | -4,323.81% | -13,276.29% | 0.00% |
| Research & Development | 6.33M | 7.01M | 8.89M | 4.43M | 4.30M | 4.33M | 5.37M | 5.42M | 6.93M | 5.68M | 17.65M | 10.45M | 6.62M |
| General & Administrative | 4.29M | 4.45M | 4.63M | 4.36M | 4.71M | 3.18M | 4.01M | 3.62M | 3.35M | 3.22M | 3.70M | 2.62M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 4.29M | 4.45M | 4.63M | 4.36M | 4.71M | 3.18M | 4.01M | 3.62M | 3.35M | 3.22M | 3.70M | 2.62M | 6.15M |
| Other Expenses | -6.13M | -18.00K | 224.00K | -1.00K | 79.00K | 4.00K | 4.70M | 3.11M | 2.44M | 2.21M | 2.63M | 0.00 | 0.00 |
| Operating Expenses | 4.49M | 11.46M | 13.51M | 8.79M | 9.01M | 7.50M | 9.38M | 9.03M | 10.27M | 8.90M | 21.35M | 13.07M | 12.77M |
| Cost & Expenses | 10.82M | 11.46M | 13.51M | 8.79M | 9.01M | 7.50M | 9.38M | 9.03M | 10.27M | 8.90M | 21.35M | 13.07M | 12.77M |
| Interest Income | 0.00 | 0.00 | 0.00 | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 24.00K | 30.00K | 0.00 |
| Depreciation & Amortization | 184.00K | 193.00K | 192.00K | 183.00K | 67.00K | 81.00K | 70.00K | 53.00K | 77.00K | 87.00K | 99.00K | 147.00K | 163.00K |
| EBITDA | -10.64M | -11.29M | -13.09M | -8.72M | -8.92M | -7.28M | -14.00M | -8.96M | -10.16M | -8.74M | -20.85M | -12.70M | -15.16M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -42,795.24% | -5,336.23% | -31,060.00% | -47,557.89% | -30,102.94% | -12,443.66% | -5,225.56% | -13,353.61% | 0.00% |
| Operating Income | -10.82M | -11.46M | -13.51M | -8.79M | -8.99M | -7.36M | -14.06M | -9.02M | -10.24M | -8.83M | -20.95M | -12.98M | -12.77M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -42,795.24% | -5,336.23% | -93,746.67% | -47,447.37% | -30,108.82% | -12,430.99% | -5,250.38% | -13,376.29% | 0.00% |
| Total Other Income/Expenses | -2.00K | -18.00K | 224.00K | -1.00K | 79.00K | 4.00K | -11.00K | 21.00K | 14.00K | 26.00K | 24.00K | 108.00K | 2.55M |
| Income Before Tax | -10.83M | -11.48M | -13.29M | -8.79M | -8.91M | -7.36M | -14.07M | -8.99M | -10.22M | -8.80M | -20.93M | -12.88M | -10.22M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -42,419.05% | -5,333.33% | -93,820.00% | -47,336.84% | -30,067.65% | -12,394.37% | -5,244.36% | -13,278.35% | 0.00% |
| Income Tax Expense | 0.00 | -175.00K | -75.00K | -134.30K | -67.00K | 4.00K | -1.62M | -74.00K | -91.00K | -113.00K | 0.00 | -95.00K | -2.55M |
| Net Income | -10.83M | -11.31M | -13.21M | -8.79M | -8.84M | -7.36M | -12.45M | -8.99M | -10.22M | -8.80M | -20.93M | -12.88M | -10.22M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -42,100.00% | -5,333.33% | -83,013.33% | -47,336.84% | -30,067.65% | -12,394.37% | -5,244.36% | -13,278.35% | 0.00% |
| EPS | -46.87 | -89.61 | -111.32 | -207.25 | -2.07K | -6.22K | -32.80K | -79.28K | -93.03K | -238.08K | -1.06M | -1.45M | -1.30M |
| EPS Diluted | -46.76 | -89.61 | -111.32 | -207.25 | -2.07K | -6.22K | -32.80K | -79.28K | -93.03K | -238.08K | -1.06M | -1.45M | -1.30M |
| Weighted Avg Shares Out | 231.00K | 126.16K | 118.68K | 42.43K | 4.26K | 1.18K | 379.62 | 113.44 | 109.89 | 36.96 | 19.76 | 8.88 | 7.88 |
| Weighted Avg Shares Out (Dil) | 231.51K | 126.16K | 118.68K | 42.43K | 4.26K | 1.18K | 379.62 | 113.44 | 109.89 | 36.96 | 19.76 | 8.88 | 7.88 |
Phio Pharmaceuticals Presents Data at ESMO 2021 Demonstrating Persistent Anti-Tumor Immunity with INTASYL Dual-Targeting PD-1 and BRD4
MARLBOROUGH, Mass., Sept. 16, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced results of a new study showing that...
Phio Pharmaceuticals to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference September 13th-15th
MARLBOROUGH, Mass., Sept. 3, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced that it will participate in the H.C.
Phio Pharmaceuticals Announces Upcoming Data Presentation at the ESMO Virtual Congress 2021
MARLBOROUGH, Mass., Aug. 31, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced that new data in support of upcoming...
Precarious Market Action
Precarious Market Action
Phio Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update
MARLBOROUGH, Mass., Aug. 12, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today reported its financial results for the quarter ended June...
Phio Pharmaceuticals Scheduled to Participate in a Fireside Chat with H.C. Wainwright on July 12th
MARLBOROUGH, Mass., July 7, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced that it will participate in a Fireside...
Phio Pharmaceuticals Reschedules Fireside Chat Hosted by H.C. Wainwright for July 12th
MARLBOROUGH, Mass., June 22, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced that it has rescheduled the Company's fireside chat...
Phio Pharmaceuticals Scheduled to Participate in Two Upcoming Investor Events in June
MARLBOROUGH, Mass., June 14, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced that its Chief Executive Officer, Dr. Gerrit Dispersyn,...
Phio Pharmaceuticals Presents New In Vivo Data at the 2021 ASCO Annual Meeting Showing Dual-Targeting INTASYL Offers Increased Efficacy and Safety Potential Over Other Therapeutic Approaches
MARLBOROUGH, Mass., June 4, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced positive in vivo data that provide further...
Phio Pharma's PH-762 Shows Encouraging Antitumor Efficacy In Preclinical Studies
Phio Pharmaceuticals Corp (NASDAQ: PHIO) stock falls despite the company announcing positive new in vivo data showing that PH-762 significantly enhanced the antitumor efficacy of HER2-targeted CAR-T cells (HER2CART) in solid tumors. Compared to untreated, HER2CART cells treated with PH-762 showed statistically significant and...
Source: https://incomestatements.info
Category: Stock Reports